You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Dopamine receptor agonist and anti-Parkinson's agent. Displays high affinity for D2, D3 and D4 receptors along with 5-HT1A. Exhibits some 5-HT2B receptor antagonist properties. Decreases prolactin release; reduces inflammatory mediators such as TNF-α and IL6. Exhibits anticonvulsive effects. Acts similar to bromocriptine (Cat. No. 0427).
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 454.52. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.2 mL||11 mL||22 mL|
|5 mM||0.44 mL||2.2 mL||4.4 mL|
|10 mM||0.22 mL||1.1 mL||2.2 mL|
|50 mM||0.04 mL||0.22 mL||0.44 mL|
References are publications that support the biological activity of the product.
Hofmann et al (2006) Lisuride, a DA receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis Clin.Neuropharmacol. 29 80 PMID: 16614540
Zweckberger et al (2010) Anticonvulsive effects of the DA agonist lisuride maleate after experimental traumatic brain injury. Neurosci.Lett. 470 150 PMID: 20056133
Woitalla et al (2004) Transdermal lisuride delivery in the treatment of Parkinson's disease. J.Neural Transm. 68 89
If you know of a relevant reference for Lisuride maleate, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Lisuride maleate, Lisuride maleate supplier, antiparkinsonian, drug, anti-Parkinson's, disease, dopaminergic, agonists, dopamine, receptor, agonist, DA, Non-selective, Dopamine, 5-HT, 4052, Tocris Bioscience
3 Citations for Lisuride maleate
Citations are publications that use Tocris products. Selected citations for Lisuride maleate include:
Gadgaard & Jensen (2020) Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay. Biochem Pharmacol 175 PMID: 32088264
Chan et al (2018) Coalescing beneficial host and deleterious antiparasitic actions as an antischistosomal strategy. Elife 7 PMID: 30059006
McCorvy et al (2018) Structural determinants of 5-HT2B receptor activation and biased agonism. Nat Struct Mol Biol 25 787 PMID: 30127358
Do you know of a great paper that uses Lisuride maleate from Tocris? Please let us know.
Reviews for Lisuride maleate
There are currently no reviews for this product. Be the first to review Lisuride maleate and earn rewards!
Have you used Lisuride maleate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.